Top

ADHD Attention Deficit and Hyperactivity Disorders

Published in:

Open Access 01-12-2011 | Original Article

Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials

Authors: Alexander Schacht, Rodrigo Escobar, Thomas Wagner, Peter M. Wehmeier

Published in: ADHD Attention Deficit and Hyperactivity Disorders | Issue 4/2011

Abstract

Our aim was to evaluate the psychometric properties of the generic quality of life (QoL) scale Child Health and Illness Profile-Child Edition (CHIP-CE) by means of a combined analysis of atomoxetine clinical trials in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Individual patient-level data from five clinical trials were included in the combined analysis. Psychometric properties of the CHIP-CE were explored in terms of internal consistency and structure. Patients (n = 794) aged between 6 and 15 years (mean 9.7) with mean baseline ADHD Rating Scale of 41.8 ± 8.04 were included. On average, 0.7 (SD 2.23) items were missing for the whole CHIP-CE. The internal consistency of the CHIP-CE assessed by Cronbach’s alpha was good for all sub-domains at baseline and at endpoint. Considerable ceiling effects were only observed for the “restricted activity” sub-domain. No considerable floor effects were seen. The factor analysis supported the 12-factor solution for the sub-domains, but not the 5-factor solution for the domains. Our analyses were based on a large sample of non-US patients which allowed the measurement of clear changes in QoL over time. The results support that the CHIP-CE scale is psychometrically robust over time in terms of internal consistency and structure.

American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC

Barkley RA (2002) Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63(Suppl 12):10–15PubMed

Bastiaens L (2008) Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic. Psychiatr Q 79:133–137 (published online)

Biederman J, Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366:237–248PubMedCrossRef

Brown RT, Perwien A, Faries DE, Kratochvil CJ, Vaughan BS (2006) Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. Clin Pediatr (Phila) 45:819–827CrossRef

Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, Fagan J, Gadoros J, Harpin V, Hazell P, Johnson M, Lerman-Sagie T, Soutullo CA, Wolanczyk T, Zeiner P, Fouche DS, Krikke-Workel J, Zhang S, Michelson D, for the Atomoxetine International Study Group (2004) A prospective, multi-center, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry 13:249–257PubMed

Cheng JY, Chen RY, Ko JS, Ng EM (2007) Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents. Meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 194:197–209CrossRef

Curatolo PP, Mancini F, Dell’Agnello G, the LYCY Study Group (2007) Quality of life of pediatric patients with attention-deficit/hyperactivity disorder and opposite defiant disorder: an Italian double-blind placebo-controlled study with atomoxetine. Poster presented at the XIII ESCAP congress, 25–29 Aug, Florence, Italy

DeVellis RF (1991) Scale development: theory and applications. Sage, Newbury Park

Dickson RA, Jackiewicz G, Khattak S, Gilchrist W, Szombathy S, Brunner E, Moroz T, Lee B (2007) Change in ADHD symptoms and functional outcomes in Canadian children during 3 months of atomoxetine treatment. Poster presented at the 27th annual conference of the Canadian Academy of Child and Adolescent Psychiatry (CACAP), 11–13 Nov, Montreal, QC

Döpfner M, Steinhausen H-C, Coghill D, Dalsgaard S, Poole L, Ralston SJ, Rothenberger A, ADORE Study Group (2006) Cross-cultural reliability and validity of ADHD assessed by the ADHD rating scale in a pan-European study. Eur Child Adolesc Psychiatry 15(Suppl 1):i46–i55PubMedCrossRef

DuPaul GJ, Ervin RA, Hook CL, McGoey KE (1998a) Peer tutoring for children with attention deficit hyperactivity disorder: effects on classroom behavior and academic performance. J Appl Behav Anal 31:579–592PubMedCrossRef

DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998b) ADHD rating scale-IV: checklists, norms, and clinical interpretations. Guilford, New York

Escobar R, Soutullo CA, Hervas A, Gastaminza X, Polavieja P, Gilaberte I (2005) Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 116:e364–e369PubMedCrossRef

Escobar R, Hervas A, Soutullo C, Mardomingo MJ, Uruñuela A, Gilaberte I (2008) Attention deficit/hyperactivity disorder: burden of the disease according to subtypes in recently diagnosed children. Actas Esp Psiquiatr 36(5):285–294

Escobar R, Montoya A, Polavieja P, Cardo E, Artigas J, Hervas A, Fuentes J (2009) Evaluation of patients’ and parents’ quality of life in a randomized placebo-controlled atomoxetine study in ADHD. J Child Adolesc Psychopharmacol 19(3):253–263

Escobar R, Schacht A, Wagner T, Wehmeier PM (2010) Quality of life and ADHD core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials. J Clin Psychopharmacol 30:145–151PubMedCrossRef

Faries DE, Yalcin I, Harder D, Heiligenstein JH (2001) Validation of the ADHD rating scale as a clinician administered and scored instrument. J Atten Disord 5:39–47CrossRef

Guy W (ed) (1976) ECDEU assessment manual for psychopharmacology. Publication ADM 76-338. US Department of Health, Education and Welfare, Washington, DC, pp 218–222

Hakkart-van Roijen L, Zwirs BWC, Bouwmans C, Tan SS, Schulpen TWJ, Vlasveld L, Buitelaar JK (2007) Societal cost and quality of life of children suffering from attention deficit hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry 16:316–326CrossRef

Harpin VA (2005) The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 90(Suppl 1):i2–i7PubMedCrossRef

National Institute of Mental Health (NIMH) (1985) Psychopharmacol Bull 21:839–943

Jensen PS, Hinshaw SP, Swanson JM, Greenhill LL, Conners CK, Arnold LE, Abikoff HB, Elliott G, Hechtman L, Hoza B, March JS, Newcorn JH, Severe JB, Vitiello B, Wells K, Wigal T (2001) Findings from the NIMH multimodal treatment study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr 22:60–73PubMedCrossRef

Johnston C, Mash EJ (2001) Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev 4:183–207PubMedCrossRef

Klassen AF, Miller A, Fine S (2004) Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 114:e541–e547PubMedCrossRef

Landgraf J, Abetz L, Ware J (1996) Child health questionnaire (CHQ): a users manual. Integrated Therapeutics Group, Boston

Leidy NK, Revicki DA, Geneste B (1999) Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 2:113–127PubMedCrossRef

Matza LS, Rentz AM, Secnik K, Swensen AR, Revicki DA, Michelson D, Spencer T, Newcorn JH, Kratochvil CJ (2004) The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 25:166–174PubMedCrossRef

Matza LS, Stoeckl MN, Shorr JM, Johnston JA (2006) Impact of atomoxetine on health-related quality of life and functional status in patients with ADHD. Expert Rev Pharmacoecon Outcomes Res 6:379–390PubMedCrossRef

Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee R, Spencer T, Atomoxetine ADHD Study Group (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:e83–e91PubMedCrossRef

Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, García-Polavieja MJ, Gilaberte I, Escobar R (2009) Randomized controlled trial of atomoxetine first-line treatment of newly-diagnosed, treatment-naïve cases of attention deficit/hyperactivity disorder. Curr Med Res Opin 25(11):2745–2754

Nijmeijer JS, Minderaa RB, Buitelaar JK, Mulligan A, Hartman CA, Hoekstra PJ (2008) Attention-deficit/hyperactivity disorder and social dysfunctioning. Clin Psychol Rev 28:692–708PubMedCrossRef

Perwien AR, Faries DE, Kratochvil CJ, Sumner CR, Kelsey DK, Allen AJ (2004) Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J Dev Behav Pediatr 25:445CrossRef

Perwien AR, Kratochvil CJ, Faries DE, Vaughan BS, Spencer T, Brown RT (2006) Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes? J Child Adolesc Psychopharmacol 16:713–724PubMedCrossRef

Polanczyk G, Silva de Lima M, Lessa Horta B, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942–948PubMedCrossRef

Prasad S, Hapin V, Poole L, Zeitlin H, Jamdar S, Puvanendran on behalf of the SUNBEAM Study Group (2007) A multicentre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin 23:379–394PubMedCrossRef

Rajmil L, Berra S, Estrada MD, Serra-Sutton V, Rodríguez M, Borrell C, Riley A, Starfield B (2004) Spanish version of the child health and illness profile-child edition parent report form [CHIP-CE/PRF]. Gac Sanit 18:305–311PubMed

Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, Rothman M (2000) Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 9:887–900PubMedCrossRef

Riley AW, Robertson J, Forrest CB, Green B, Rebok G, Starfield B (2001) Manual for the child health and illness profile-child edition (CHIP-CE). The Johns Hopkins University, Baltimore

Riley AW, Forrest CB, Rebok GW, Starfield B, Green BF, Robertson JA, Friello P (2004a) The child report form of the CHIP-child edition: reliability and validity. Med Care 42:221–231PubMedCrossRef

Riley AW, Forrest CB, Starfield B, Rebok GW, Robertson JA, Green BF (2004b) The parent report form of the CHIP-child edition: reliability and validity. Med Care 42:210–220PubMedCrossRef

Riley AW, Coghill D, Forrest CB, Lorenzo MJ, Ralston SJ, Spiel G, ADORE Study Group (2006a) Validity of the health-related quality of life assessment in the ADORE study: parent report form of the CHIP-child edition. Eur Child Adolesc Psychiatry 15(Suppl 1):i63–i71PubMedCrossRef

Riley AW, Spiel G, Coghill D, Döpfner M, Falissard B, Lorenzo MJ, Preuss U, Ralston SJ, ADORE Study Group (2006b) Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment. Eur Child Adolesc Psychiatry 15(Suppl 1):i38–i45PubMedCrossRef

Riley AW, Chan KS, Prasad S, Poole L (2007) A global measure of child health-related quality of life: reliability and validity of the child health and illness profile-child edition (CHIP-CE) global score. J Med Econ 10:91–106CrossRef

Sawyer MG, Whaites L, Rey JM, Hazell PL, Graetz BW, Baghurst P (2002) Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry 41:530–537PubMedCrossRef

Schmidt LJ, Garratt AM, Fitzpatrick R (2001) Child/parent-assessed population health outcome measures: a structured review. Child Health Care Dev 28:227–237CrossRef

Svanborg P, Thernlund G, Gustafsson PA, Hägglöf B, Poole L, Kadesjö B (2009) Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention-deficit/hyperactivity disorder—a randomized, double-blind placebo controlled study in stimulant-naïve Swedish children and adolescents. Eur Child Adolesc Psychiatry 18:240–249PubMedCrossRef

Wallander JL, Schmitt M, Koot HM (2001) Quality of life measurements in children and adolescents: issues, instruments, and applications. J Clin Psychol 57:571–585PubMedCrossRef

Wehmeier PM, Dittmann RW, Schacht A, Minarzyk A, Lehmann M, Sevecke K, Lehmkuhl G (2007) Effectiveness of atomoxetine in children with attention-deficit/hyperactivity disorder and quality of life as perceived by patients, parents and physicians in an open-label study. J Child Adolesc Psychopharmacol 17:813–830PubMedCrossRef

Wehmeier PM, Schacht A, Lehmann M, Dittmann RW, Silva SG, March JS (2008) Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective. Child Adolesc Psychiatry Mental Health 2:10 (published online)

Yang P, Hsu HY, Chiou SS, Chao MC (2007) Health-related quality of life in methylphenidate-treated children with attention-deficit/hyperactivity disorder: results from a Taiwanese sample. Aust NZ J Psychiatry 41:998–1004CrossRef

Title: Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials
Authors: Alexander Schacht
Rodrigo Escobar
Thomas Wagner
Peter M. Wehmeier
Publication date: 01-12-2011
Publisher: Springer Vienna
Published in: ADHD Attention Deficit and Hyperactivity Disorders / Issue 4/2011
Print ISSN: 1866-6116
Electronic ISSN: 1866-6647
DOI: https://doi.org/10.1007/s12402-011-0066-y

At a glance: The STEP trials

Springer Medicine

Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

An exploration of the associations of pregnancy and perinatal features with cytokines and tryptophan/kynurenine metabolism in children with attention-deficit hyperactivity disorder (ADHD)

The screens culture: impact on ADHD

Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study

Effects of DSP4 and methylphenidate on spatial memory performance in rats